ICON Public (NASDAQ:ICLR) PT Lowered to $275.00 at Barclays

by · The Markets Daily

ICON Public (NASDAQ:ICLR – Free Report) had its target price cut by Barclays from $330.00 to $275.00 in a research note published on Friday, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Several other equities analysts have also commented on the stock. Robert W. Baird lowered shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price objective for the company. in a research report on Thursday. Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday. Evercore ISI dropped their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Leerink Partners reduced their target price on ICON Public from $376.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday. Finally, StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and a consensus target price of $310.45.

View Our Latest Report on ICON Public

ICON Public Price Performance

NASDAQ ICLR opened at $220.47 on Friday. The firm’s fifty day simple moving average is $297.75 and its two-hundred day simple moving average is $310.18. The firm has a market capitalization of $18.19 billion, a P/E ratio of 25.70, a P/E/G ratio of 1.35 and a beta of 1.22. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36. ICON Public has a 12-month low of $220.01 and a 12-month high of $347.72.

ICON Public (NASDAQ:ICLR – Get Free Report) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter last year, the firm earned $3.10 earnings per share. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. Analysts forecast that ICON Public will post 14.53 EPS for the current fiscal year.

Institutional Trading of ICON Public

A number of hedge funds and other institutional investors have recently modified their holdings of ICLR. EverSource Wealth Advisors LLC lifted its holdings in shares of ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after acquiring an additional 42 shares during the last quarter. Motco grew its stake in shares of ICON Public by 1.5% in the first quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after buying an additional 59 shares in the last quarter. First National Bank of Hutchinson increased its stake in ICON Public by 5.7% during the 1st quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock worth $381,000 after buying an additional 61 shares during the period. Arkadios Wealth Advisors lifted its position in shares of ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after buying an additional 62 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of ICON Public by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after buying an additional 87 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Company Profile

(Get Free Report)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Articles